Junichi Takagi
Plus aucun poste en cours
Profil
Junichi Takagi worked as a Manager at Panasonic Holdings Corp., a Principal at Ascii Corp., and a Senior General Manager at CSK Co., Ltd.
He also worked as a Manager-Finance at UMN Pharma, Inc. from 2007 to 2009.
Takagi holds an MBA from George Washington University and an undergraduate degree from Keio University.
Anciens postes connus de Junichi Takagi
| Sociétés | Poste | Fin |
|---|---|---|
| PANASONIC HOLDINGS CORPORATION | Corporate Officer/Principal | - |
| Ascii Corp. | Corporate Officer/Principal | - |
CSK Co., Ltd.
 CSK Co., Ltd. Engineering & ConstructionIndustrial Services Part of EXEO Group, Inc., CSK Co., Ltd. provides civil engineering and pavement services. The company is based in Nagoya, Japan. CSK Co. was acquired by C-Cube Corp., part of EXEO Group, Inc. from October 01, 2018 on August 31, 2004 for $0.20 million. | Corporate Officer/Principal | - |
| UMN PHARMA INC. | Directeur Financier/CFO | 01/04/2009 |
Formation de Junichi Takagi
| George Washington University | Masters Business Admin |
| Keio University | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PANASONIC HOLDINGS CORPORATION | Consumer Durables |
| Entreprise privées | 3 |
|---|---|
| Ascii Corp. | Technology Services |
CSK Co., Ltd.
CSK Co., Ltd. Engineering & ConstructionIndustrial Services Part of EXEO Group, Inc., CSK Co., Ltd. provides civil engineering and pavement services. The company is based in Nagoya, Japan. CSK Co. was acquired by C-Cube Corp., part of EXEO Group, Inc. from October 01, 2018 on August 31, 2004 for $0.20 million. | Industrial Services |
UMN Pharma, Inc.
 UMN Pharma, Inc. Pharmaceuticals: MajorHealth Technology UMN Pharma, Inc. engages in the development, manufacture, and sale of biopharmaceuticals. It operates through a following business division: Next-generation biopharmaceutical in-house development business and Biopharmaceutical contract manufacturing business. The Next-generation biopharmaceutical in-house development business engages in the research and development of next-generation logical vaccine by integrating next-generation biopharmaceutical drug substance manufacturing technology, adjuvant technology and drug delivery technology. The Biopharmaceutical contract manufacturing business offers study samples, investigational drugs, products, and various evaluation test results. The company was founded by Masahiro Michishita and Shuichi Kanazashi on April 20, 2004 and is headquartered in Akita, Japan. | Health Technology |
